[{"orgOrder":0,"company":"Galecto","sponsor":"Linical | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Linical | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Linical | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Covance"},{"orgOrder":0,"company":"Galecto","sponsor":"QPS Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Undisclosed","graph2":"Phase I","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ QPS Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Galecto \/ QPS Holdings"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Galecto","sponsor":"Comac Medical","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Comac Medical","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Comac Medical"},{"orgOrder":0,"company":"Galecto","sponsor":"Providence Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Providence Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Providence Cancer Institute"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Providence Cancer Center | Earle A. Chiles Research Institute | Galecto","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Oncology","graph2":"Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Providence Cancer Center | Earle A. Chiles Research Institute | Galecto","highestDevelopmentStatusID":"8","companyTruncated":"Providence Health & Services \/ Providence Cancer Center | Earle A. Chiles Research Institute | Galecto"}]

Find Clinical Drug Pipeline Developments & Deals for GB1211

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GB1211, galectin-3 inhibitor, in combination with pembrolizumab is being investigated for the treatment of metastatic malignant melanoma and head and neck squamous cell carcinoma

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 01, 2024

                          Lead Product(s) : GB1211,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Providence Health & Services

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Providence Health & Services

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Lead Product(s) : GB1211

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Providence Cancer Center | Earle A. Chiles Research Institute | Galecto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : GB1211 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 22, 2023

                          Lead Product(s) : GB1211

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Providence Cancer Center | Earle A. Chiles Research Institute | Galecto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GB1211 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 28, 2023

                          Lead Product(s) : GB1211

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : QPS Holdings

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GB1211 demonstrated improvement and consistent signs of activity across biochemical liver function markers and markers of target engagement, apoptosis, and fibrosis, including reductions in galectin-3 (p<0.05) and CK-18 (M65) (p<0.002).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 08, 2022

                          Lead Product(s) : GB1211

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GB1211 is an orally available and potent small molecule galectin-3 inhibitor. Initial target indications for GB1211 are liver cirrhosis, severe, progressive disease that ultimately leads to liver failure, and NSCLC.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 31, 2022

                          Lead Product(s) : GB1211,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Preclinical data has shown that GB1211 has the ability to reduce galectin-3-induced checkpoint inhibitor blockages, thus preventing galectin-3 from inducing checkpoint inhibitor resistance.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 19, 2022

                          Lead Product(s) : GB1211,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Providence Cancer Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GB1211 is an orally available and potent small molecule galectin-3 inhibitor. Galecto’s initial target indications for GB1211 are liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure, and non-small cell lung cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 17, 2022

                          Lead Product(s) : GB1211

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GB1211 reversed the galectin-3 induced blockage of the checkpoint inhibitors atezolizumab and pembrolizumab and increased the effects of these checkpoint inhibitors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 29, 2022

                          Lead Product(s) : GB1211,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Clinical evidence patients suggests high levels of galectin-3 in tumors leads to resistance to treatment with checkpoint inhibitors. In multiple pre-clinical models, GB1211 has been shown to reduce tumor growth and metastasis and increase efficacy of che...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 16, 2022

                          Lead Product(s) : GB1211,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GB1211 demonstrated an anti-cancer effect and antifibrotic activity in multiple preclinical models and has successfully completed a Phase 1 trial in 78 healthy volunteers. In the Phase 1 trial, GB1211 was well-tolerated and exhibited dose-dependent pharm...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : GB1211,Atezolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank